A physical examination with vital signs, complete blood cell counts with differentials, and blood chemistry tests were performed before every administration of gemcitabine in each subsequent cycle. Toxicity was evaluated and graded according to version 4.0 of the Common Terminology Criteria for Adverse Events of the National Cancer Institute. All of the patients who received at least one dose of treatment were included in the toxicity assessment. For the toxicity analysis, the data indicating the worst toxicity for each patient from all of the chemotherapy cycles were used. The proportion of patients who experienced adverse events was calculated by dividing the number of patients who experienced adverse events during the treatment period by the number of patients evaluable for safety analysis. Response to treatment according to RECIST version 1.1 was evaluated every 2 cycles. Patients with CR or PR required a confirmatory disease assessment at least 4 weeks later. PFS was defined as the interval from the date of treatment initiation to the first date of documented disease progression or death due to any cause. OS was defined as the interval from the date of treatment initiation to the date of death.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.